tirzepatide in mash Hepatoprotective effects of semaglutide and the GAN diet-induced obese and biopsy-confirmed mouse model of In the SYNERGY-NASH trial, researchers

As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions

GLP-1 Receptor Agonists (GLP-1 RAs):Primary mechanism: Mimicking the GLP-1 hormone to regulate appetite, blood sugar, and potentially influencing brain reward pathways.Common side effects: Nausea, vomiting, diarrhea, constipation (often gastrointestinal).Potential benefits for mood: Indirect effects through weight management, reduced "food noise," and possible anti-inflammatory actions

Originally developed to treat type 2 diabetes, Semaglutide has been approved for weight loss under the brand name Wegovy

Non-fiber-based laxative use has also Laxative misuse often requires medical help for both physical and mental treatment